» Articles » PMID: 38591087

MicroRNA-630 Alleviates Inflammatory Reactions in Rats with Diabetic Kidney Disease by Targeting Toll-like Receptor 4

Overview
Specialty Endocrinology
Date 2024 Apr 9
PMID 38591087
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Diabetic kidney disease (DKD) is a major complication of diabetes mellitus. Renal tubular epithelial cell (TEC) damage, which is strongly associated with the inflammatory response and mesenchymal trans-differentiation, plays a significant role in DKD; However, the precise molecular mechanism is unknown. The recently identified microRNA-630 (miR-630) has been hypothesized to be closely associated with cell migration, apoptosis, and autophagy. However, the association between miR-630 and DKD and the underlying mechanism remain unknown.

Aim: To investigate how miR-630 affects TEC injury and the inflammatory response in DKD rats.

Methods: Streptozotocin was administered to six-week-old male rats to create a hyperglycemic diabetic model. In the second week of modeling, the rats were divided into control, DKD, negative control of lentivirus, and miR-630 overexpression groups. After 8 wk, urine and blood samples were collected for the kidney injury assays, and renal tissues were removed for further molecular assays. The target gene for miR-630 was predicted using bioinformatics, and the association between miR-630 and toll-like receptor 4 (TLR4) was confirmed using investigations and double luciferase reporter gene assays. Overexpression of miR-630 in DKD rats led to changes in body weight, renal weight index, basic blood parameters and histopathological changes.

Results: The expression level of miR-630 was reduced in the kidney tissue of rats with DKD ( < 0.05). The miR-630 and TLR4 expressions in rat renal TECs (NRK-52E) were measured using quantitative reverse transcription polymerase chain reaction. The mRNA expression level of miR-630 was significantly lower in the high-glucose (HG) and HG + mimic negative control (NC) groups than in the normal glucose (NG) group ( < 0.05). In contrast, the mRNA expression level of TLR4 was significantly higher in these groups ( < 0.05). However, miR-630 mRNA expression increased and TLR4 mRNA expression significantly decreased in the HG + miR-630 mimic group than in the HG + mimic NC group ( < 0.05). Furthermore, the levels of tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and IL-6 were significantly higher in the HG and HG + mimic NC groups than in NG group ( < 0.05). However, the levels of these cytokines were significantly lower in the HG + miR-630 mimic group than in the HG + mimic NC group ( < 0.05). Notably, changes in protein expression were observed. The HG and HG + mimic NC groups showed a significant decrease in E-cadherin protein expression, whereas TLR4, α-smooth muscle actin (SMA), and collagen IV protein expression increased ( < 0.05). Conversely, the HG + miR-630 mimic group exhibited a significant increase in E-cadherin protein expression and a notable decrease in TLR4, α-SMA, and collagen IV protein expression than in the HG + mimic NC group ( < 0.05). The miR-630 targets TLR4 gene expression. In vivo experiments demonstrated that DKD rats treated with miR-630 agomir exhibited significantly higher miR-630 mRNA expression than DKD rats injected with agomir NC. Additionally, rats treated with miR-630 agomir showed significant reductions in urinary albumin, blood glucose, TLR4, and proinflammatory markers (TNF-α, IL-1β, and IL-6) expression levels ( < 0.05). Moreover, these rats exhibited fewer kidney lesions and reduced infiltration of inflammatory cells.

Conclusion: MiR-630 may inhibit the inflammatory reaction of DKD by targeting TLR4, and has a protective effect on DKD.

Citing Articles

MicroRNA-630: A potential guardian against inflammation in diabetic kidney disease.

Madhoun A World J Diabetes. 2024; 15(9):1837-1841.

PMID: 39280181 PMC: 11372643. DOI: 10.4239/wjd.v15.i9.1837.


MicroRNA-630: A promising avenue for alleviating inflammation in diabetic kidney disease.

Donate-Correa J, Gonzalez-Luis A, Diaz-Vera J, Hernandez-Fernaud J World J Diabetes. 2024; 15(7):1398-1403.

PMID: 39099820 PMC: 11292322. DOI: 10.4239/wjd.v15.i7.1398.

References
1.
Gholaminejad A, Tehrani H, Fesharaki M . Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies. J Nephrol. 2018; 31(6):813-831. DOI: 10.1007/s40620-018-0511-5. View

2.
Liu F, Chen J, Luo C, Meng X . Pathogenic Role of MicroRNA Dysregulation in Podocytopathies. Front Physiol. 2022; 13:948094. PMC: 9277480. DOI: 10.3389/fphys.2022.948094. View

3.
Bai X, Hou X, Tian J, Geng J, Li X . CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via ERK1/2/PPARγ pathway. Oncotarget. 2016; 7(24):36510-36528. PMC: 5095017. DOI: 10.18632/oncotarget.9058. View

4.
Wang H, Wang S, Chiufai K, Wang Q, Cheng X . Umbelliferone ameliorates renal function in diabetic nephropathy rats through regulating inflammation and TLR/NF-κB pathway. Chin J Nat Med. 2019; 17(5):346-354. DOI: 10.1016/S1875-5364(19)30040-8. View

5.
Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besancon S . Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020; 162:108072. DOI: 10.1016/j.diabres.2020.108072. View